Aaron D. Goldberg, MD, PhD
Leukemia Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Adult Acute and Chronic Leukemias
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
Request an Appointment
About Me
- Assistant Attending Physician
I am a hematologist and medical oncologist who specializes in caring for people with leukemia and myelodysplastic syndrome. I am board-certified in hematology, medical oncology, and internal medicine. I work as part of a team of doctors and nurses with wide-ranging expertise to bring the most-advanced, comprehensive care in the world to our patients and their families.
Read more
Patients often come to me with deep concerns about how their disease will affect their lives. I treat every patient as if they are a member of my family. As a physician, I take time to listen to their concerns and provide thorough answers. As a scientist, I study the molecular features of each patient’s disease to determine which specific therapy will work best to treat them.
At MSK, we have many clinical trials that give our patients access to groundbreaking therapies. These include immunotherapy, epigenetic therapy, and other small-molecule targeted approaches. I lead multiple clinical trials evaluating new treatments designed to specifically target leukemia.
Working with scientific collaborators, I also study leukemia in the laboratory. Our long-term goal is to provide more effective and less toxic therapies for people with acute myeloid leukemia. My colleagues and I are working to advance our field so that we can continue to offer our patients options beyond traditional treatments, such as chemotherapy.
Every day I reflect on what an extraordinary privilege it is to care for people with leukemia and other blood disorders. I hope that all of my patients leave a visit with me knowing that I will work tirelessly to provide them with the best possible care.
A leukemia specialist is a doctor with special training in diagnosing and treating leukemia.
My Specialties
- Adult Acute and Chronic Leukemias
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Myeloproliferative Neoplasms (MPNs)
- Immunotherapy
Education
- MD, Weill Cornell Medical College
- PhD, Rockefeller University
Residencies
- Internal Medicine - Brigham and Women’s Hospital
Awards and Honors
- American Society of Hematology Fellow Scholar Award in Clinical Research (2018)
- Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Oncology/Hematology Clinical Research Award (2017)
- American Society of Clinical Oncology Young Investigator Award (2017)
- Memorial Sloan Kettering Cancer Center Chief Hematology Fellow (2016)
- Resident Mentor Award, Brigham and Women’s Hospital (2014)
- Franklyn Ellenbogen Prize in Hematology-Oncology, Weill Cornell Medical College (2011)
Fellowships
- Hematology/Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Goldberg sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Goldberg
- A Phase 1 Study of Ziftomenib Combinations in People With Acute Myeloid Leukemia
- A Phase III Study of Crenolanib or Midostaurin after Induction and Consolidation Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia
- Clinical Trials Co-Investigated by Dr. Goldberg
- A Phase 1 Study of ABBV-787 in People With Acute Myeloid Leukemia
- A Phase 1 Study of BH-30236 in People With Acute Myelogenous Leukemia or Higher-Risk Myelodysplastic Syndrome
Read more
- A Phase 1 Study of GLB-001 in People With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
- A Phase 1 Study of KT-253 in People With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, and Myelodysplastic Syndrome
- A Phase 1 Study of REM-422 in People With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
- A Phase 1 Study of SGR-2921 in People With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- A Phase 1B Study of Gilteritinib Plus Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia
- A Phase I Study of BTX-A51 in People with Recurrent or Persistent Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- A Phase I Study of FHD-286 in People with Recurrent or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndromes
- A Phase I/II Study of SNDX-5613 in People with Recurrent or Persistent Acute Leukemia
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Goldberg’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Aaron D. Goldberg discloses the following relationships and financial interests:
-
AbbVie
Professional Services and Activities -
Astellas
Professional Services and Activities -
Bristol-Myers Squibb
Professional Services and Activities -
Dava Oncology
Professional Services and Activities
-
Ikena Oncology
Professional Services and Activities -
Kura Oncology
Professional Services and Activities -
Molecular Partners
Professional Services and Activities -
Syndax
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].